I:SPX Oct 2023 Weekly 3100.000 Stock Price, News & Analysis

Infinity Pharmaceuticals (NASDAQ: INFI) plans to initiate the MARIO-4 registration study for eganelisib in frontline metastatic triple-negative breast cancer (mTNBC) by the end of 2022. The company reports promising tumor volume reductions of up to 92.8% in PD-L1(+) mTNBC patients. Additionally, the MARIO-P platform study will commence in 3Q 2022 to explore other solid tumor indications. Infinity projects a net loss of $45 million to $55 million for 2022 while expecting to end the year with $25 million to $35 million in cash. Multiple data releases are anticipated in the second half of 2022.

Infinity Pharmaceuticals (NASDAQ: INFI) has been added to the NASDAQ Biotechnology Index (NBI), effective December 20, 2021. This index tracks companies in biotechnology and pharmaceuticals, requiring a minimum market capitalization of $200 million and an average daily trading volume of 100,000 shares. CEO Adelene Perkins highlighted the recognition of Infinity's progress, particularly regarding the clinical data for eganelisib, an oral immuno-oncology treatment. This milestone is pivotal for the company's ongoing efforts to deliver innovative cancer treatments.

Infinity Pharmaceuticals is featured in B. Riley’s Fall 2021 Growth Biotech “Best Ideas” series, with a fireside chat scheduled for December 14, 2021, at 2:30 PM ET. The discussion will include notable speakers such as Key Opinion Leader Hatem Soliman, MD, Infinity's CEO Adelene Perkins, and CMO Robert Ilaria.

The session will focus on Infinity's lead drug, eganelisib, an oral immuno-oncology treatment targeting PI3K-gamma, aimed at addressing immune suppression in cancer.

Infinity Pharmaceuticals (NASDAQ: INFI) presented updated data from its MARIO-3 clinical study at the 2021 San Antonio Breast Cancer Symposium. The study evaluates eganelisib in combination with atezolizumab and nab-paclitaxel for frontline metastatic triple-negative breast cancer (TNBC). Key findings include a tumor reduction in 88.6% of evaluable patients and a disease control rate of 92.8% for PD-L1 positive tumors. The median progression-free survival (PFS) improved by 47% for PD-L1 positive and 30% for PD-L1 negative patients compared to the IMpassion130 benchmark.

Infinity Pharmaceuticals (NASDAQ: INFI) is hosting an investor event on December 10 at 9:30 AM ET, focusing on the MARIO-3 Phase 2 study of eganelisib in combination with Tecentriq® and Abraxane® for frontline triple-negative breast cancer (TNBC). Key Opinion Leader Dr. Hatem Soliman will present data on the study's design, patient demographics, and updated safety and efficacy results. The event will feature a Q&A session and aims to address the significant unmet medical needs in frontline metastatic TNBC.

Infinity Pharmaceuticals, Inc (NASDAQ: INFI) has announced that CEO Adelene Perkins will present at the 33rd Annual Virtual Healthcare Conference on November 22. This presentation will include a fireside chat with Piper's Senior Biotech Analyst, Ted Tenthoff, and will be available on Infinity's website. Additionally, management will hold 1-on-1 investor meetings from November 29 to December 2. Infinity is developing eganelisib, an oral immuno-oncology therapeutic targeting immune suppression in cancer.

Infinity Pharmaceuticals reported promising clinical data for eganelisib, indicating a meaningful extension of progression-free survival (PFS) in both PD-L1(-) and PD-L1(+) metastatic triple-negative breast cancer (mTNBC) patients, surpassing benchmarks set by the IMpassion130 study. Additionally, eganelisib showed a 7.5-month increase in overall survival for metastatic urothelial cancer patients compared to the control arm. The company appointed new leadership, including a Chief Scientific Officer and Chief Medical Officer. For Q3 2021, Infinity reported a net loss of $10.7 million and expects a net loss between $40 million and $50 million for the year.

Infinity Pharmaceuticals (NASDAQ: INFI) will host a conference call on November 2, 2021, at 4:30 PM ET to discuss its financial results for Q3 2021. The call will feature updates on eganelisib, a novel immuno-oncology treatment aimed at managing tumor immune suppression. This includes progress on various clinical studies: MARIO-275, MARIO-3, and MARIO-1, which explore eganelisib's efficacy in combination with other therapies for advanced cancers. Interested parties can access the call via webcasting on Infinity's website.

Infinity Pharmaceuticals (NASDAQ: INFI) has announced its participation in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit as well as the 3rd Annual Macrophage-directed Therapies Summit. The Oppenheimer event will include a live presentation on September 20 at 1:15 PM ET, along with 1-on-1 meetings from September 20 to 22. The Macrophage-directed Therapies Summit will take place on September 30 at 4:00 PM ET, focusing on the synergistic potential of eganelisib with frontline treatments. Further details are available on Infinity's website.